Rationale: Systemic sclerosis (SSc) is characterized by widespread microangiopathy, fibrosis, and autoimmunity.
sels by inducing vasodilation, proliferation, and migration of endothelial cells, invasion of the surrounding stroma by endothelial cells, and stabilization of the vascular lumen. 5 Vascular endothelial growth factor A (VEGF-A, hereafter referred to as VEGF) is one of the major proangiogenic regulators and is found to be overexpressed in most physiological and pathological angiogenic states. 5 Several studies have shown that VEGF expression is markedly increased in different cell types both in the epidermis and dermis of patients with SSc. 3, 6 VEGF exerts its biological functions by binding to the tyrosine kinase receptors VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1/KDR), both of which are upregulated on dermal microvascular endothelial cells in SSc-affected skin. 3, 6 Moreover, a number of studies demonstrated that circulating levels of VEGF are significantly increased in SSc patients throughout different disease stages and correlate with organ manifestations. 3 However, in SSc, there is no evidence of effective angiogenesis, and the disease evolves toward a progressive loss of capillary vessels. 3 Collectively, this scenario has been regarded as a paradox. Indeed, the cellular and molecular mechanisms responsible for the lack of a sufficient angiogenic response to chronic ischemia in the presence of elevated proangiogenic mediators remain largely unknown. 3 The VEGF gene consists of 8 exons separated by 7 introns and spans approximately 14 kb. 7 VEGF pre-mRNA is differentially spliced to form mRNAs that encode at least 6 isoforms that have been widely studied and accepted as proangiogenic and vascular propermeability factors. 8 The main isoform is VEGF 165 , which has 165 amino acids in the final structure. However, recent evidence indicates that 2 families of VEGF proteins are formed by alternative spliceacceptor-site selection in the 3Ј untranslated region within the terminal exon 8 to give 2 different C-terminal sequences that differ in only 6 amino acids. 9, 10 Proximal splice-acceptor-site selection in exon 8 results in classic proangiogenic VEGF xxx isoforms that contain the exon 8a sequence, whereas distal splice-acceptor-site selection results in antiangiogenic VEG-F xxx b isoforms that contain the exon 8b sequence (where xxx denotes the amino acid number). 10 The proangiogenic isoforms encode a terminal 6 -amino acid sequence of Cys-Asp-Lys-Pro-Arg-Arg, whereas the antiangiogenic isoforms encode Ser-Leu-Thr-Arg-Lys-Asp. The most widely studied VEGF xxx b isoform is VEGF 165 b, but other isoforms have also been identified at both the mRNA and protein levels. 10 VEGF 165 b transcript and protein are widely expressed in most healthy human tissues and in nonangiogenic tissues, although unlike other VEGF isoforms, VEGF 165 b is downregulated in angiogenic conditions, such as renal, prostate, colon, and skin cancers and proliferative diabetic retinopathy. 9, [11] [12] [13] [14] In contrast, in nonangiogenic pathological conditions, such as glaucoma, the antiangiogenic VEGF xxx b isoforms are upregulated. 15 VEGF 165 b protein was shown to significantly and dose dependently inhibit VEGF 165 -mediated proliferation and migration of endothelial cells, vasodilation of mesenteric arteries, and angiogenesis in 2 different models of VEGF 165driven blood vessel growth. 11 Furthermore, it has been shown to inhibit hypoxia-driven angiogenesis in the retina and the growth of a variety of human tumor xenografts in mice. 13,16 -18 Indeed, the dimerization and receptor-binding domains are still present in VEGF 165 b, and hence, it acts as a competitive inhibitor of VEGF 165 ; it binds to the receptor but does not stimulate the full tyrosine phosphorylation of the VEGFR-2 and downstream signaling activated by VEGF 165 . 11 VEGF 165 b therefore appears to be an endogenous antiangiogenic agent formed by alternative splicing.
Recent studies have shown that regulation of alternative splicing by growth and splicing factors is a key event in determining the relative expression of proangiogenic versus antiangiogenic VEGF isoforms. 10, 19, 20 VEGF 165 b expression is upregulated by some growth factors, such as the profibrotic transforming growth factor-␤1 (TGF-␤1) cytokine, through the activation of p38 mitogen-activated protein kinase (MAPK) and the CDC-like kinase Clk-1/Sty splicing factor kinase family pathways. 19 In this context, the mRNA-binding protein serine/arginine protein 55 (SRp55, also known as splicing factor arginine/serine-rich 6 [SFRS6]) has been identified as a key regulatory splicing factor that binds to VEGF pre-RNA in the exon 8 region and promotes distal splice-site selection and subsequent upregulation of exon 8b-containing VEGF 165 b. 19 Because the amino acid structure of antiangiogenic VEGF 165 b is 95% to 96% identical to that of VEGF 165 , 10, 11 all previous studies that have investigated VEGF expression in SSc could not distinguish between the proangiogenic and antiangiogenic VEGF isoforms. Indeed, those studies were conducted before the discovery of antiangiogenic VEGF isoforms or used in situ hybridization riboprobes, antibodies, and ELISAs that pick up both VEGF 165 and VEGF 165 b isoforms. 6, [21] [22] [23] [24] [25] We therefore undertook the present study to investigate whether the expression of VEGF splicing variants could be altered in the skin and circulation of patients with SSc.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org and includes detailed information regarding the following: characteristics of patients with SSc and healthy subjects used for collection of forearm skin biopsy samples, plasma samples, and isolation of dermal microvascular endothelial cells (MVECs); cell culture and stimulation protocols; semiquantitative reverse transcription-polymerase chain reaction (RT-PCR); quantitative real-time RT-PCR; antibodies; immunoprecipitation and Western blotting on tissue and cell protein lysates; immunohistochemistry and confocal laser scanning microscopy; ELISAs on plasma samples and culture supernatants; in vitro capillary morphogenesis assay; and statistical analysis. 26 Fifteen patients had limited cutaneous SSc (lcSSc) and 20 had diffuse cutaneous SSc (dcSSc) according to the criteria proposed by LeRoy et al. 27 Patients were further classified as being in the early (nϭ21) or late (nϭ14) phase of SSc according to disease duration and to the clinical and pathological stage of skin involvement, as detailed in the Online Data Supplement. The characteristics of patients used for collection of skin biopsy samples are listed in Online Table I . After mRNA extraction from skin biopsy samples and cDNA synthesis, cDNA was amplified with exon 4/exon 8b-specific primers that detect the VEGF 165 b splice variant only or exon 4/exon 8a-specific primers that pick up proangiogenic VEGF 165 but not antiangiogenic VEGF 165 b. Because previous studies have shown that VEGF 165 b mRNA is downregulated whereas VEGF 165 mRNA is upregulated in renal cancer, 9 we used renal cell carcinoma samples as an additional disease control group for the RT-PCR assay. As shown in Figure 1A , VEGF 165 b mRNA was detected in all skin biopsy samples from SSc patients and healthy subjects, whereas VEGF 165 mRNA was weakly expressed or even almost undetectable in both groups. As expected in renal cell carcinoma, VEGF 165 b mRNA was weakly expressed, whereas VEGF 165 mRNA was highly expressed. VEGF 165 b mRNA was found to be upregulated in the majority of SSc skin samples compared with healthy control subjects ( Figure  1A) . Quantitative real-time RT-PCR confirmed that VEGF 165 b transcript levels were significantly increased in SSc skin compared with control skin (PϽ0.001; Figure 1B ).
Non-standard Abbreviations and Acronyms
To analyze VEGF 165 b protein expression, skin sections from patients with SSc and healthy subjects were immunostained with a mouse monoclonal antibody that specifically detects the VEGF 165 b splice variant but not proangiogenic VEGF 165 . 11, 12 This antibody is raised to the 9 C-terminal amino acids of human VEGF 165 b, the final 6 of which are specific to VEGF 165 b. 11 To confirm antibody specificity, the anti-VEGF 165 b antibody was used to probe a blot of an SDS-polyacrylamide gel loaded with recombinant human VEGF 165 b and VEGF 165 . Figure 2A shows that this antibody specifically recognized VEGF 165 b and did not detect VEGF 165 . In contrast, anti-pan-VEGF antibodies detect both VEGF 165 b and VEGF 165 isoforms.
Consistent with recent findings, 14 constitutive expression of VEGF 165 b was observed in both the epidermis and dermis of healthy control subjects ( Figures 2B and 2C ). Whereas in the majority of healthy subjects, the expression of VEGF 165 b ranged from weak to moderate ( Figure 2B ), an intense immunopositivity was found in keratinocytes, dermal fibroblasts, and capillary vessels of 6 of 23 control samples ( Figure 2C ). A marked upregulation of VEGF 165 b was found in the majority of affected skin biopsy samples from patients with SSc ( Figures 2D-H) . In both early and late SSc skin, an enhanced expression of VEGF 165 b could be detected in epidermal keratinocytes and in the papillary and reticular dermis, where it was found in fibroblasts and microvascular endothelial cells (Figures 2D-F). In early SSc skin, perivascular inflammatory cells infiltrating the dermis were also strongly immunopositive for VEGF 165 b ( Figure 2D ). Furthermore, in early SSc, endothelial cells and vascular smooth muscle cells of dermal arterioles and large inflammatory infiltrates found in the hypodermis also showed a strong expression of VEGF 165 b ( Figures 2G and 2H ). Double-labeling experiments with an antibody against the pan-endothelial cell marker CD31 confirmed the expression of VEGF 165 b in endothelial cells and perivascular inflammatory cells ( Figures 2I and 2J ). Semiquantitative analysis of immunofluorescent staining intensity on skin sections showed that VEGF 165 b expression was increased significantly in both the epidermis and dermal cells of patients with SSc (both PϽ0.001 compared with healthy control subjects; Figure 2K ).
The pattern of VEGF 165 b expression observed in the skin of SSc patients was very similar to that described previously for VEGF in different studies. 6, 21, 22 However, previous studies detected VEGF in SSc skin specimens using in situ hybridization riboprobes or antibodies that recognize both VEGF 165 and VEGF 165 b isoforms. 6,21,22 Therefore, we immunostained serial skin sections from SSc patients with the VEGF 165 b-specific antibody and 3 different pan-VEGF antibodies that react with both VEGF 165 and VEGF 165 b (see the Online Data Supplement). Staining with the VEGF 165 bspecific antibody revealed that in both normal and SSc skin, VEGF 165 b was expressed in the same cells as the pan-VEGF stain, and with a very similar intensity ( Figure 3A ). In fact, in a semiquantitative analysis, no significant difference in immunofluorescent staining intensity could be found. Each of the 3 pan-VEGF antibodies gave similar results. Moreover, double immunostaining with mouse anti-VEGF 165 b antibody and rabbit anti-pan-VEGF antibody revealed that the 2 markers were almost completely colocalized in the same tissue structures ( Figure 3B ).
Western blotting was used to evaluate VEGF 165 b and pan-VEGF expression levels in crude protein extracts from whole skin samples. Both VEGF 165 b-specific antibody and pan-VEGF antibodies detected a prominent protein band with a molecular weight of 23 kDa, which is consistent with the monomeric forms of both VEGF 165 b and VEGF 165 ( Figure  3C ). Moreover, both antibodies revealed a smaller band with a molecular weight of 46 kDa, consistent with the persistence of small amounts of VEGF 165 b and VEGF 165 homodimers under standard reducing conditions ( Figure 3C ). In accordance with our findings, it has been reported previously that the anti-VEGF 165 b antibody recognizes both the VEGF 165 b monomer and dimer in Western blotting experiments. 11, 15 In additional Western blotting experiments with stronger reducing conditions, only the VEGF 165 b monomer (23 kDa) could be detected (Online Figure I) . Western blotting results paralleled those obtained by immunohistochemistry. In skin from patients with SSc, there was a statistically significant increase in both VEGF 165 b and pan-VEGF protein expression levels compared with skin from healthy subjects (both PϽ0.001; Figure 3D ). Indeed, blot bands obtained with the VEGF 165 bspecific antibody were equivalent in intensity to those obtained with pan-VEGF antibodies in the same individual skin samples ( Figure 3C ). In fact, densitometric analysis did not reveal any significant difference between VEGF 165 b and pan-VEGF protein levels in either SSc or control skin samples ( Figure 3D ). In addition, in a blot of an SDS-polyacrylamide gel loaded with different concentrations of recombinant human VEGF 165 b, anti-VEGF 165 b and anti-pan-VEGF antibodies detected bands of comparable intensity for the same amounts of loaded protein ( Figure 3E ). This indicates that the 2 antibodies recognize VEGF 165 b protein with the same affinity. Moreover, the preincubation of anti-VEGF 165 b antibody with an excess of recombinant human VEGF 165 b protein, but not preincubation with recombinant human VEGF 165 , abolished the blot stainings, which further indicates that the anti-VEGF 165 b antibody specifically detected VEGF 165 b in skin protein extracts assayed in Western blotting experiments (Online Figure I) . Collectively, these data indicate that almost all the VEGF protein detectable in both SSc and control skin specimens was the antiangiogenic VEGF 165 b isoform.
No significant difference in skin expression of VEGF 165 b was found between patients with lcSSc and those with dcSSc. Instead, VEGF 165 b protein levels were higher in early SSc than in late SSc skin ( Figure 3C ). This was consistent with the immunohistochemical findings. In fact, in addition to keratinocytes, endothelial cells, and fibroblasts, infiltrating inflammatory cells also showed strong expression of VEGF 165 b in early SSc skin ( Figures 2D, 2H , and 2J).
VEGF 165 b Levels Are Raised in the Circulation of Patients With SSc
Blood samples were obtained from 61 patients with SSc (36 lcSSc and 25 dcSSc; 28 early and 33 late SSc phase) and 30 age-and sex-matched healthy subjects. The characteristics of patients used for collection of blood samples are listed in Online Table II . Circulating levels of VEGF 165 b were measured in SSc and control plasma with a quantitative sandwich ELISA that does not cross-react to proangiogenic VEGF isoforms (see the Online Data Supplement).
Plasma levels of VEGF 165 b were significantly higher in SSc patients (median 288.76 pg/mL, range 56.43 to 1056.0 pg/mL) than in healthy control subjects (median 137.34 pg/mL, range 0 to 351.75 pg/mL; PϽ0.001; Figure 4A ). No significant difference was detected between lcSSc (median 242.42 pg/mL, range 75.21 to 1056.0 pg/mL) and dcSSc (median 299.69 pg/mL, range 56.43 to 993.72 pg/mL). Circulating levels of VEGF 165 b were significantly higher in both lcSSc and dcSSc than in control subjects (both Pϭ0.002; Figure 4A ). Plasma VEGF 165 b was increased significantly in both the early (median 305.14 pg/mL, range 69.58 to 1056.0 pg/mL) and late (median 249.63 pg/mL, range 56.43 to 985.79 pg/mL) SSc phase compared with healthy control subjects (Pϭ0.001 and Pϭ0.004, respectively), whereas it was not different between early and late SSc ( Figure 4B ).
We also analyzed circulating levels of pan-VEGF in SSc and control subjects using an ELISA that recognizes both VEGF 165 and VEGF 165 b. Pan-VEGF levels were in the range of those detected for VEGF 165 b with VEGF 165 b-specific ELISA. Pan-VEGF levels were significantly raised in SSc patients (median 323.13 pg/mL, range 67.94 to 1291.08 pg/mL) compared with healthy subjects (median 153.87 pg/mL, range 0 to 433.50 pg/mL; PϽ0.001; Figure 4C ). Pan-VEGF was significantly higher in the circulation of both lcSSc (median 278.85 pg/mL, range 87.24 to 1193.71 pg/mL) and dcSSc (median 387.81 pg/mL, range 67.94 to 1291.08 pg/mL) than in control subjects (Pϭ0.002 and PϽ0.001, respectively; Figure 4C ), whereas it was not different between lcSSc and dcSSc. No significant difference was detected between the early (median 368.37 pg/mL, range 92.15 to 1178.24 pg/mL) and late (median 314.22 pg/mL, range 67.94 to 1291.08 pg/mL) SSc phase. Circulating pan-VEGF levels were significantly elevated in both early and late SSc compared with control subjects (PϽ0.001 and Pϭ0.001, respectively; Figure 4D ). Collectively, the findings of pan-VEGF ELISA paralleled those obtained with VEGF 165 bspecific ELISA and indicated that the majority of circulating VEGF in both SSc and control subjects was the VEGF 165 b splice variant.
In SSc Skin, VEGFR-2 Is Upregulated and Coexpressed With VEGF 165 b in Endothelial Cells
Recent studies have shown that VEGF 165 b binds to VEGFR-2 with the same affinity as VEGF 165 but does not activate proangiogenic signals. 10, 11 We therefore performed double immunohistochemistry with antibodies against VEGF 165 b and VEGFR-2 on skin sections from SSc patients and control subjects. In control skin, very weak or no expression of VEGFR-2 could be observed ( Figure 5A ). Consistent with previous reports, 6,21 the expression of VEGFR-2 was found to be significantly upregulated in SSc skin biopsy samples (PϽ0.001 compared with control subjects), and no dermal structures other than endothelial cells expressed VEGFR-2 ( Figures 5B-D) . In both the papillary and reticular dermis of SSc skin, VEGF 165 b and VEGFR-2 were upregulated and coexpressed in endothelial cells ( Figures 5B and 5C ). Quantitative real-time RT-PCR confirmed that VEGFR-2 transcript levels were significantly increased in SSc compared with control skin (PϽ0.001; Figure 5E ).
Upregulated VEGF 165 b Correlates With Increased Expression of TGF-␤1 and SRp55 Splicing Factor in SSc Skin
It has been demonstrated recently that growth factors, especially TGF-␤1, and splicing factors, particularly SRp55, can preferentially select for the distal splice site in the VEGF pre-mRNA terminal exon 8, thus resulting in upregulation of the VEGF 165 b isoform. 10, 19 We therefore performed double immunohistochemistry to investigate whether the expression of VEGF 165 b in affected skin from patients with SSc could be correlated with the expression of TGF-␤1 and SRp55.
Consistent with previous findings, 1,28 we observed a strong expression of profibrotic TGF-␤1 in the affected skin of SSc patients ( Figure 6 ). The expression of TGF-␤1 correlated well with that of VEGF 165 b. Indeed, the 2 cytokines were coexpressed in different cell types, including keratinocytes, dermal fibroblasts, endothelial cells, and perivascular inflammatory cells ( Figure 6) .
Although in the majority of control skin specimens, the expression of SRp55 ranged from weak to moderate ( Figure  7A ; Online Figure II, A) , an intense immunopositivity was found in the 6 of 23 control subjects who also showed increased VEGF 165 b expression. A strong upregulation of SRp55 was observed in the affected skin biopsy samples from SSc patients ( Figure 7A ; Online Figure II, A) . In SSc skin, upregulated SRp55 and VEGF 165 b were coexpressed in both the epidermis and dermis, with an intense doubleimmunopositive signal in keratinocytes, fibroblasts, endothelial cells, and perivascular infiltrating inflammatory cells ( Figure 7A ; Online Figure II, A) . Western blotting analysis on skin tissue homogenates revealed that SRp55 expression levels were increased significantly in SSc patients (PϽ0.001 compared with control subjects; Figure 7B and Online Figure  II, B) . Moreover, SRp55 protein levels were higher in early than in late SSc skin. No significant difference in SRp55 expression was found between skin specimens from patients with lcSSc and those with dcSSc.
Expression of VEGF 165 b and SRp55 Is Increased and Modulated by TGF-␤1 in Dermal MVECs Isolated From SSc Skin
Dermal MVECs were isolated from forearm biopsy samples of involved skin from 6 patients with dcSSc and from 6 healthy subjects (see the Online Data Supplement). Pan-endothelial cell marker CD31 staining yielded positive results in more than 90% of the cell population. No difference in cell density, once at confluence, was observed between healthy MVECs and SSc MVECs, which allowed us to perform experiments in conditions of similar cell density.
The basal protein expression of VEGF 165 b and SRp55 was higher in SSc MVECs than in healthy MVECs ( Figure 8A) . Moreover, stimulation with TGF-␤1 upregulated the expression of VEGF 165 b and SRp55 in both SSc and healthy MVECs ( Figure 8A ). As determined by ELISA, SSc MVECs constitutively released significantly higher levels of VEGF 165 b in culture supernatant compared with healthy MVECs (PϽ0.001). After TGF-␤1 stimulation, the levels of VEGF 165 b in culture supernatants were significantly increased in both SSc 
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and healthy MVECs (both PϽ0.001 compared with unstimulated cells; Figure 8A ).
Increased Levels of Antiangiogenic VEGF 165 b in SSc MVECs Lead to Impaired VEGFR-2 Phosphorylation and Downstream Signaling and Result in Defective Angiogenesis
Consistent with findings of immunohistochemical staining on skin sections, the basal protein expression of VEGFR-2 was found to be increased in SSc MVECs compared with healthy MVECs ( Figure 8B) ; however, immunoprecipitation with antiphosphotyrosine antibodies and subsequent Western blotting analysis with anti-VEGFR-2 antibodies revealed that only a small amount of VEGFR-2 was phosphorylated in SSc MVECs. Indeed, levels of phosphorylated VEGFR-2 were strongly reduced in SSc MVECs compared with healthy MVECs (Figure 8B ). In agreement with previous reports, 11 we found that healthy MVECs had a basal level of VEGFR-2 phosphorylation that was strongly increased by recombinant VEGF 165 and decreased by VEGF 165 b. Moreover, VEGF 165 b was able to inhibit VEGF 165 -mediated VEGFR-2 phosphorylation ( Figure 8B ). Treatment of healthy MVECs with SSc-MVEC-conditioned medium decreased VEGFR-2 phosphorylation compared with basal cells. However, the addition of anti-VEGF 165 b blocking antibodies to SSc-MVEC-condi-tioned medium not only abrogated this inhibitory effect but also resulted in increased VEGFR-2 phosphorylation levels in healthy MVECs ( Figure 8B ). We then investigated the downstream signaling pathways that are activated in MVECs after VEGFR-2 phosphorylation. SSc MVECs had lower levels of phosphorylated extracellular signal-regulated kinase 1/2 (phospho-ERK1/2) MAPK than healthy MVECs (Online Figure III) . Conversely, phosphorylation of Akt was not different between SSc MVECs and healthy MVECs. Although treatment with proangiogenic VEGF 165 resulted in a strong increase of phospho-ERK1/2 in healthy MVECs, this was not the case for incubation with VEGF 165 b alone or in combination with VEGF 165 (Online Figure III) . Incubation with SSc-MVEC-conditioned medium reduced the levels of phospho-ERK1/2, whereas the addition of anti-VEGF 165 b blocking antibodies to SSc-MVEC-conditioned medium resulted in increased phospho-ERK1/2 in healthy MVECs (for the comparison with untreated cells, see Online Figure III ). Conversely, treatment with VEGF 165 b or SSc-MVEC-conditioned medium did not affect phosphorylation of Akt in healthy MVECs.
Using an in vitro capillary morphogenesis assay, we observed that the ability of healthy MVECs to form tubular structures on Matrigel was strongly potentiated by treatment with recombinant VEGF 165 , whereas it was inhibited by VEGF 165 b ( Figure 8C ). In addition, VEGF 165 b was able to inhibit VEGF 165 -mediated sprouting angiogenesis (Figure 8C) . SSc-MVEC-conditioned medium also showed an inhibitory effect on healthy MVEC angiogenesis. Conversely, the addition of anti-VEGF 165 b blocking antibodies to SSc-MVEC-conditioned medium resulted in stimulation of healthy MVEC angiogenesis ( Figure 8C ). As shown previously, 29, 30 capillary morphogenesis was severely impaired in SSc MVECs. Compared with healthy MVECs, after 6 hours of plating on Matrigel, SSc MVECs were unable to spontaneously produce elongated processes and to organize as branching cords. After 24 hours, SSc MVECs formed aggregates of cells but were unable to spontaneously organize into a honeycomb morphological pattern, producing only an incomplete endothelial network ( Figure 8C ). Stimulation of SSc MVECs with recombinant VEGF 165 at 10 ng/mL resulted in a slight promotion of angiogenesis. The use of recombinant VEGF 165 at 50 ng/mL significantly increased capillary morphogenesis in SSc MVECs. The combination of proangiogenic VEGF 165 (50 ng/mL) and anti-VEGF 165 b blocking antibodies further promoted the sprouting angiogenic response in SSc MVECs, reaching levels comparable to those observed in basal healthy MVECs ( Figure 8C ).
Discussion
Our data show for the first time that the endogenous antiangiogenic VEGF 165 b splice variant is selectively upregulated in SSc skin and circulation and that this property is retained in cultured dermal MVECs isolated from patients' skin.
Moreover, we provide evidence that profibrotic TGF-␤1 and SRp55 splicing factor may contribute to the switch from proangiogenic to antiangiogenic VEGF isoforms and that constitutive overexpression of antiangiogenic VEGF 165 b leads to impaired VEGFR-2 downstream signaling and capillary morphogenesis in SSc MVECs. Finally, our in vitro findings suggest that neutralization of elevated VEGF 165 b might represent a potential strategy to promote an effective angiogenic response in patients with SSc.
Since its discovery in 1983, VEGF has raised interest because of its role in neovascularization in a variety of physiological and pathological processes, such as the female reproductive cycle, wound healing, cancers, myocardial ischemia, and rheumatoid arthritis and other autoimmune diseases. 31 VEGF participates in many different steps of angiogenesis, including initial vasodilation, endothelial cell permeability, remodeling of the perivascular matrix, and induction of proliferation and migration of endothelial cells. 32 These proangiogenic effects are mediated principally by activation of VEGFR-2. [32] [33] [34] In fact, phosphorylation of ERK1/2 MAPK, Akt, and p38 MAPK by VEGFR-2 activation appears to be necessary for the promotion of endothelial cell proliferation, resistance to apoptosis, migration through extracellular matrix, and formation of a vascular lumen. [32] [33] [34] Endothelial cells also express VEGFR-1, but its specific role in endothelial physiology is less well defined and somewhat controversial. 33, 34 VEGF is highly upregulated in all cases of pathological angiogenesis described to date. 31, 35 VEGF 165 , VEGF 189 , and VEGF 121 are commonly overexpressed, but VEGF 165 appears to predominate quantitatively and functionally in most angiogenic states. 35 Recent studies, however, demonstrated that the VEGF primary transcript can be alternatively spliced in terminal exon 8, producing mRNA splice variants that are translated to proangiogenic and antiangiogenic isoforms. 9 -11 These splice variants differ by 6 amino acids at the C-terminus that switch the properties of these variants from proangiogenic to antiangiogenic activity. 9 -11 The predominant antiangiogenic isoform is VEGF 165 b, which binds to VEGFR-2 with the same affinity as VEGF 165 but does not activate receptor phosphorylation or stimulate downstream intracellular signaling pathways. 10, 11 VEGF 165 b competitively inhibits VEGF 165 -mediated proangiogenic activity, which results in the inhibition of endothelial cell proliferation and migration in vitro and neovascularization in different experimental models. 10,11,13,16 -18 The amino acid structure of VEGF 165 b is 95% to 96% identical to that of VEGF 165 . 10, 11 To date, the majority of studies that investigated VEGF expression in healthy and diseased tissues could not distinguish between the proangiogenic and antiangiogenic VEGF isoforms.
In 2004, Woolard et al 11 showed that a monoclonal antibody raised against the terminal 9 -amino acid sequence of human VEGF 165 b could specifically detect antiangiogenic VEGF 165 b but not proangiogenic VEGF 165 . By contrast, there is no commercially available antibody that specifically detects only the VEGF 165 isoform. 10 With the VEGF 165 bspecific antibody, it could be demonstrated that VEGF 165 b is widely expressed in most healthy human tissues, as well as in human plasma, with levels consistent with known circulating levels of VEGF. 10, 11 VEGF 165 b has been reported to be downregulated in all cancers investigated thus far, as well as in other angiogenic conditions such as proliferative diabetic retinopathy and Denys-Drash syndrome. 10 -14,16 -18 Several previous studies reported an increased expression of VEGF in SSc skin and circulation but could not distinguish between the VEGF 165 and VEGF 165 b isoforms. 6, [21] [22] [23] [24] [25] In the present study, we used VEGF 165 b-specific primer pairs and antibodies and were able to show that antiangiogenic VEGF 165 b is selectively upregulated at both the mRNA and protein levels in the affected skin of SSc patients. Moreover, we provided evidence that circulating levels of VEGF 165 b are raised in SSc. Our data also indicate that almost all VEGF detected in SSc skin and circulation is the antiangiogenic VEGF 165 b and that increased levels of VEGF 165 b are both early and persistent features of the disease. In addition, we found that dermal MVECs isolated from SSc skin constitutively overexpress and release high levels of VEGF 165 b in the culture supernatant.
Consistent with previous reports, 6, 21 we confirmed the upregulation of VEGFR-2 on endothelial cells in SSc skin, a property that is also retained in cultured SSc MVECs. This might be interpreted as a frustrated attempt to provide effective angiogenesis through proangiogenic VEGF 165 /VEGFR-2 signal-ing enhancement in endothelial cells. However, in SSc, upregulated antiangiogenic VEGF 165 b may bind to endothelial VEGFR-2 with the same affinity as VEGF 165 , 11 thus preventing VEGFR-2 phosphorylation and downstream signaling and ultimately resulting in an insufficient angiogenic response to chronic tissue ischemia. Indeed, here we have shown that VEGFR-2 phosphorylation, activation of ERK1/2 MAPK, and capillary morphogenesis are impaired in SSc MVECs. We also found that in healthy MVECs, VEGFR-2 phosphorylation, downstream ERK1/2 activation, and angiogenesis may be significantly inhibited by treatment with recombinant VEGF 165 b or SSc-MVEC-conditioned medium that contains elevated levels of VEGF 165 b. Interestingly, the addition of anti-VEGF 165 b blocking antibodies to SSc-MVEC-conditioned medium not only prevented these inhibitory effects but even resulted in the promotion of healthy MVEC angiogenesis. Moreover, we also show that although severely impaired, SSc MVEC angiogenesis can be ameliorated by treatment with the combination of high-dose proangiogenic VEGF 165 and anti-VEGF 165 b neutralizing antibodies. Taken together, these data indicate that the uncontrolled expression of VEGF 165 b may have an important role in the defective angiogenesis found in SSc. It will be of interest to further explore whether signaling of VEGF 165 b through VEGFR-1 or neuropilin-1 may also be involved in SSc vasculopathy.
Finally, we also found in SSc skin a marked overexpression of the profibrotic TGF-␤1 cytokine and SRp55 splicing factor that was strikingly correlated with increased levels of VEGF 165 b in different cell types. Cultured SSc MVECs also appeared to constitutively overexpress SRp55. Furthermore, we observed that stimulation of MVECs with TGF-␤1 re-sulted in the upregulation of SRp55 and VEGF 165 b. Both TGF-␤1 and SRp55 have previously been reported to favor distal splice-site selection in the exon 8 region of VEGF pre-RNA, leading to the upregulation of VEGF 165 b in vitro. 10, 19 In the case of SRp55, this appears to occur through direct binding to the VEGF pre-RNA. 19 Conditional overexpression of SRp55 was shown to upregulate VEGF 165 b relative to the VEGF 165 isoform, whereas SRp55 knockdown reduced expression of VEGF 165 b. 19 In SSc, elevated expression of TGF-␤1 and SRp55 may therefore contribute to the switch from proangiogenic to antiangiogenic VEGF isoforms. TGF-␤1 is known to be a key cytokine that drives the fibrotic process of SSc. 1, 28 Therefore, the present results may also identify a novel link between 2 of the major aspects of SSc pathogenesis, ie, progressive fibrosis and vascular damage with lack of compensatory angiogenesis. Translational studies on preclinical animal models of SSc will further investigate the role of VEGF alternative splicing in SSc-related peripheral vascular disease.
In conclusion, the present data provide new insights into the pathogenesis of defective angiogenesis and vascular repair in SSc. Administration of proangiogenic VEGF 165 and other strategies aimed to counteract the constitutive upregulation of antiangiogenic VEGF 165 b or molecular regulation of VEGF pre-RNA splicing might represent potential therapeutic approaches to promote effective angiogenesis and capillary regeneration in SSc. 
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Novelty and Significance
What Is Known?
• Systemic sclerosis (SSc, or scleroderma) is a chronic, multisystem connective tissue disorder characterized by widespread microangiopathy, fibrosis, and autoimmunity that affects the skin and internal organs. Severe peripheral vascular complications may occur during the course of SSc. • Although in SSc there is a lack of sufficient angiogenic response to chronic tissue ischemia that culminates in the loss of capillary vessels, the expression of the potent proangiogenic mediator vascular endothelial growth factor A (VEGF) has paradoxically been shown to be upregulated in this disease. • Previous studies in the field did not distinguish between the proangiogenic VEGF 165 and antiangiogenic VEGF 165 b isoforms that are generated by alternative splicing in the terminal exon of VEGF pre-RNA.
What New Information Does This Article Contribute?
• We show that the endogenous antiangiogenic VEGF 165 b splice variant is selectively upregulated in the skin and circulation of patients with SSc and that this property is retained in cultured dermal microvascular endothelial cells (MVECs) isolated from patients' skin. • We provide evidence that profibrotic transforming growth factor-␤1 (TGF-␤1) and serine/arginine protein 55 (SRp55) splicing factor may contribute to the switch from proangiogenic to antiangiogenic VEGF isoforms and that constitutive overexpression of antiangiogenic VEGF 165 b leads to impaired VEGF receptor-2 phosphorylation and reduced downstream signaling, thus preventing SSc MVECs from entering a suitable angiogenic program in vitro.
• Our in vitro findings also suggest that neutralization of elevated VEGF 165 b might represent a potential strategy to promote an effective angiogenic response in patients with SSc.
VEGF is considered one of the major proangiogenic regulators and is found to be overexpressed in most physiological and pathological angiogenic states. Although SSc is a nonangiogenic pathological condition characterized by progressive loss of the microvasculature, a number of studies have reported increased expression of VEGF in these patients. However, recent evidence has demonstrated that the VEGF primary transcript can be alternatively spliced in terminal exon 8, producing mRNA splice variants that are translated to the proangiogenic VEGF 165 and antiangiogenic VEGF 165 b isoforms. Because the amino acid structure of VEGF 165 b is 95% to 96% identical to that of VEGF 165 , all previous studies in the field of SSc investigated VEGF expression using methodologies that could not distinguish between the proangiogenic and antiangiogenic VEGF isoforms. The present study was designed to determine whether VEGF isoform expression could be altered in the skin and circulation of patients with SSc. Here, we show that VEGF 165 b is selectively overexpressed in SSc, and we highlight the molecular mechanisms by which this antiangiogenic VEGF isoform may play a crucial role in the defective angiogenesis and vascular repair process that characterizes SSc. Our results suggest that the combination of proangiogenic VEGF 165 administration and VEGF 165 b neutralization might represent a potential therapeutic strategy to promote effective angiogenesis and capillary regeneration in SSc. 
